{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.003","pValueComment":"P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG001","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.167","pValueComment":"P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG002","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG003","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.001","pValueComment":"P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.528","value":"-0.35"},{"groupId":"OG001","spread":"0.524","value":"-0.18"},{"groupId":"OG002","spread":"0.459","value":"-0.33"},{"groupId":"OG003","spread":"0.497","value":"-0.39"},{"groupId":"OG004","spread":"0.406","value":"-0.10"}]}],"title":"Week 12"},{"categories":[{"measurements":[{"comment":"Participants were not dosed with 1 mg LY3009104 after Week 12, therefore mean and SD were not calculated.","groupId":"OG000","spread":"NA","value":"NA"},{"groupId":"OG001","spread":"0.505","value":"-0.18"},{"groupId":"OG002","spread":"0.506","value":"-0.32"},{"groupId":"OG003","spread":"0.529","value":"-0.44"},{"comment":"Participants were not dosed with placebo after Week 12, therefore mean and SD were not calculated.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Week 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"51"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"98"}],"units":"Participants"}],"description":"The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \\[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.","dispersionType":"Standard Deviation","groups":[{"description":"1 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG000","title":"1 mg LY3009104"},{"description":"2 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.\n\nMTX was administered orally as background therapy.","id":"OG001","title":"2 mg LY3009104"},{"description":"4 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.\n\nMTX was administered orally as background therapy.","id":"OG002","title":"4 mg LY3009104"},{"description":"8 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.\n\nMTX was administered orally as background therapy.","id":"OG003","title":"8 mg LY3009104"},{"description":"Placebo administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG004","title":"Placebo"}],"paramType":"MEAN","populationDescription":"All randomized participants who received study drug in Parts A and B and had HAQ-DI evaluated at analysis time points. LOCF was used to impute missing post-baseline values.","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 12 and 24","title":"Mean Change From Baseline to Weeks 12 and 24 in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score","type":"SECONDARY","unitOfMeasure":"units on a scale"}